230 related articles for article (PubMed ID: 32476802)
1. Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative.
Pitisuttithum P; Chan WK; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Dan YY; Imajo K; Nakajima A; Ho KY; Goh KL; Wong VW; Treeprasertsuk S
World J Gastroenterol; 2020 May; 26(19):2416-2426. PubMed ID: 32476802
[TBL] [Abstract][Full Text] [Related]
2. Estimation of gamma-glutamyl transferase as a suitable simple biomarker of the cardiovascular risk in children with non-alcoholic fatty liver disease.
Bobrus-Chociej A; Flisiak-Jackiewicz M; Daniluk U; Wojtkowska M; Kłusek-Oksiuta M; Tarasów E; Lebensztejn D
Acta Biochim Pol; 2018 Oct; 65(4):539-544. PubMed ID: 30380561
[TBL] [Abstract][Full Text] [Related]
3. Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study.
Pitisuttithum P; Chan WK; Piyachaturawat P; Imajo K; Nakajima A; Seki Y; Kasama K; Kakizaki S; Fan JG; Song MJ; Yoon SK; Dan YY; Lesmana L; Ho KY; Goh KL; Wong VWS; Treeprasertsuk S
BMC Gastroenterol; 2020 Apr; 20(1):88. PubMed ID: 32252638
[TBL] [Abstract][Full Text] [Related]
4. Role of γ-glutamyl transferase levels in prediction of high cardiovascular risk among patients with non-alcoholic fatty liver disease.
Kasapoglu B; Turkay C; Yalcın KS; Carlioglu A; Koktener A
Indian J Med Res; 2016 Jan; 143(1):30-6. PubMed ID: 26997011
[TBL] [Abstract][Full Text] [Related]
5. Simple biochemical parameters and a novel score correlate with absence of fibrosis in patients with nonalcoholic fatty liver disease.
Shukla A; Kapileswar S; Gogtay N; Joshi A; Dhore P; Shah C; Abraham P; Bhatia S
Indian J Gastroenterol; 2015 Jul; 34(4):281-5. PubMed ID: 26341864
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD.
Wang J; Li P; Jiang Z; Yang Q; Mi Y; Liu Y; Shi R; Zhou Y; Wang J; Lu W; Li S; Liu D
Korean J Intern Med; 2016 May; 31(3):479-87. PubMed ID: 27025268
[TBL] [Abstract][Full Text] [Related]
7. Elevated gamma-glutamyl transferase has a non-linear association with incident non-alcoholic fatty liver disease in the non-obese Chinese population: a secondary retrospective study.
Wu L; Zhang M; Hu H; Wan Q
Lipids Health Dis; 2021 Oct; 20(1):142. PubMed ID: 34689770
[TBL] [Abstract][Full Text] [Related]
8. Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative.
Chan WK; Treeprasertsuk S; Imajo K; Nakajima A; Seki Y; Kasama K; Kakizaki S; Fan JG; Song MJ; Yoon SK; Dan YY; Lesmana L; Ho KY; Goh KL; Wong VW
Aliment Pharmacol Ther; 2018 Mar; 47(6):816-825. PubMed ID: 29333610
[TBL] [Abstract][Full Text] [Related]
9. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
[TBL] [Abstract][Full Text] [Related]
10. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
Mansoor S; Yerian L; Kohli R; Xanthakos S; Angulo P; Ling S; Lopez R; Christine CK; Feldstein AE; Alkhouri N
Dig Dis Sci; 2015 May; 60(5):1440-7. PubMed ID: 25540086
[TBL] [Abstract][Full Text] [Related]
11. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study.
Tan EX; Lee JW; Jumat NH; Chan WK; Treeprasertsuk S; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Imajo K; Nakajima A; Seki Y; Kasama K; Kakizaki S; Lesmana LA; Zheng KI; Zheng MH; Koh CJ; Ho KY; Goh KL; Wong VW; Dan YY
Metabolism; 2022 Jan; 126():154911. PubMed ID: 34648769
[TBL] [Abstract][Full Text] [Related]
12. Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor.
Konishi K; Miyake T; Furukawa S; Senba H; Kanzaki S; Nakaguchi H; Yukimoto A; Nakamura Y; Watanabe T; Koizumi Y; Yoshida O; Tokumoto Y; Hirooka M; Kumagi T; Abe M; Matsuura B; Hiasa Y
Atherosclerosis; 2020 Apr; 299():32-37. PubMed ID: 32203743
[TBL] [Abstract][Full Text] [Related]
13. Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease.
Ercin CN; Dogru T; Genc H; Celebi G; Aslan F; Gurel H; Kara M; Sertoglu E; Tapan S; Bagci S; Rizzo M; Sonmez A
Metab Syndr Relat Disord; 2015 Sep; 13(7):319-25. PubMed ID: 26011302
[TBL] [Abstract][Full Text] [Related]
14. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
15. Gamma-glutamyl transpeptidase elevation is associated with metabolic syndrome, hepatic steatosis, and fibrosis in patients with nonalcoholic fatty liver disease: A community-based cross-sectional study.
Chen LW; Huang MS; Shyu YC; Chien RN
Kaohsiung J Med Sci; 2021 Sep; 37(9):819-827. PubMed ID: 34002481
[TBL] [Abstract][Full Text] [Related]
16. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
Önnerhag K; Hartman H; Nilsson PM; Lindgren S
Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
[No Abstract] [Full Text] [Related]
18. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
19. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease.
Pacifico L; Bonci E; Marandola L; Romaggioli S; Bascetta S; Chiesa C
World J Gastroenterol; 2014 Dec; 20(45):17107-14. PubMed ID: 25493023
[TBL] [Abstract][Full Text] [Related]
20. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease.
Henson JB; Simon TG; Kaplan A; Osganian S; Masia R; Corey KE
Aliment Pharmacol Ther; 2020 Apr; 51(7):728-736. PubMed ID: 32043602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
